Treehill Partners launches novel service aimed at optimizing the biotech drug development process and fostering closer collaboration between key stakeholders

Treehill Partners launches novel service aimed at optimizing the biotech drug development process and fostering closer collaboration between key stakeholders

The service has been developed to meet headwinds faced by the biotech sector, further exacerbated by a challenging financing and licensing environment

London, UK, October 17, 2023 – Treehill Partners, the global healthcare strategic and transaction advisory firm with expertise in drug development and operational restructuring, today announces the full commercial launch of a novel offering that will complement services provided by Contract Research Organizations (CROs). The Treehill service has been designed to provide each client with tailored insight that will build value, by specifically optimizing their development strategy for interaction with multiple stakeholders, raising required capital, managing investment, and developing partnerships and strategic transactions.

The service has been developed based on Treehill’s extensive work in the biotech field as well as its analysis of the long-term impact of clinical study designs on subsequent capital raises and ability to attract licensing partners. In designing this service, Treehill has evaluated over 1,200 clinical or commercial stage programs.

Stakeholder Benefits: Treehill has launched the service to benefit multiple stakeholders in the biotech ecosystem:

  • Drug developers: to better meet the intricate challenges of successful asset development that have been considerably exacerbated by the current financing and licensing environment, in addition to a sector looking to develop therapeutics for increasingly competitive disease areas.
  • Capital providers: to focus their portfolio companies on value creation over the full development timeline, enhancing return on capital and increasing strategic and transaction optionality.
  • Licensing partners: to be presented with optimized assets backed by robust strategies and clear paths to market.
  • Contract Research Organizations: the ability to offer a truly differentiated service, building stronger relationships with their clients leading to improved value creation.

Treehill’s work has thus far led to material revisions of clinical study protocols, to enhance their probability of success and improve clinical and commercial relevance. Average time-to-completion was shortened by 9 months, and the average clinical budget reduced by 15%. For CROs, there was a 20% margin improvement through providing a more tailored offering.

Research Findings: To design the service, Treehill researched itsextensive interactions with development teams of over 1,200 clinical and commercial stage programs in the biotech industry, as well as its decades of experience in operationally restructuring programs in difficulties resulting from development decisions made in the past. The research demonstrated that many clinical studies, despite being well-designed from an operational perspective, fall short of meeting expectations from investors, capital markets, strategic partners, and regulators in more than one region. In addition, many of the researched studies are not fully optimized for addressing clinical or commercial needs at time of launch.

Early Access Program: Treehill launched an early access pilot version of the service including a regional and a global top 5 CRO. The early access version demonstrated the ability of Treehill’s service to create enhanced partnerships and a layer of strategic dialogue between the CROs and their customers. The success of the early access program has enabled Treehilltofully launch the service to the wider biopharma market, focusing on optimizing individual studies and entire asset development plans.

Treehill Partners is leveraging its experienced team and strong foothold in corporate transactions and financings ecosystems to bridge the gap between CROs and the biopharma industry.

“CROs have invaluable expertise in developing drugs to regulatory approval. The path to commercial success however is complex, involving multiple stakeholders along the value chain. Companies who design their development plans to address multifaceted needs, beyond regulatory requirements, are the ones most likely to succeed,” said Ali Pashazadeh, founder and CEO, Treehill Partners. “Treehill has designed its model to fully utilize its expertise representing buy- and sell-side clients across therapeutic areas and all stages of development. This will enable Treehill and its clients to deliver direct value to patients, ultimately helping increase the number of therapies being developed successfully.”

About Treehill Partners

Treehill Partners is an international strategic and financial advisory firm exclusively focused on the healthcare sector. Its multidisciplinary team offers actionable strategic and transaction advice to healthcare CEOs, leadership teams, stakeholders, and investors, with a focus on value-creating transactions and successful corporate evolution strategies. To learn more about Treehill Partners, visit

For more information please contact: 

Subscribe to our mailings!

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.